Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

732
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
732
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

891
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
891
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Persistent Kidney Injury and Long-Term Outcomes Following Lung Transplantation.

Clinical transplantation·2026
Same author

Bacteriophages as Immune Modulators: Current Insights and Future Directions.

PHAGE (New Rochelle, N.Y.)·2026
Same author

Less severe alcoholic injury in cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) deficient mice, a possible impact of intracellular DNA recognition.

International immunopharmacology·2026
Same author

Chronic alcohol consumption compromises gut barrier integrity and promotes endotoxemia: Implications for sepsis susceptibility in immunocompromised hosts.

Animal models and experimental medicine·2026
Same author

Critical care access and outcomes in residents of inpatient-care catchment areas with and without ICUs: a nationwide cohort study in Japan.

The Lancet regional health. Western Pacific·2026
Same author

Publisher Correction: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026.

Intensive care medicine·2026

Related Experiment Video

Updated: Mar 18, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K

Mitochondrial Dysfunction in Cardiorenal Syndrome.

Kent Doi1, Eisei Noiri2

  • 11 Department of Emergency and Critical Care Medicine, The University of Tokyo , Tokyo, Japan .

Antioxidants & Redox Signaling
|June 29, 2016
PubMed
Summary

Acute kidney injury (AKI) can harm the heart, leading to cardiorenal syndrome. Our study shows AKI causes heart mitochondrial damage and apoptosis, suggesting new treatment targets.

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K
Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K

Related Experiment Videos

Last Updated: Mar 18, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K
Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics
07:03

Author Spotlight: Uncovering the Role of Mitochondrial Calcium Phosphate in Heart Failure and Bioenergetics

Published on: August 23, 2024

1.6K

Area of Science:

  • Cardiorenal physiology and pathology
  • Mitochondrial dynamics and apoptosis
  • Organ cross-talk in critical illness

Background:

  • Acute kidney injury (AKI) significantly impacts critically ill patients, with limited specific treatments.
  • Mitochondrial dysfunction and reactive oxygen species are implicated in AKI and renal damage.
  • Cardiorenal syndrome (CRS) describes interactions where heart and kidney conditions exacerbate each other.

Purpose of the Study:

  • To investigate the impact of AKI on cardiac mitochondrial dynamics and apoptosis.
  • To explore the mechanisms underlying remote organ effects of AKI on the heart.
  • To identify potential therapeutic targets for AKI-induced cardiorenal complications.

Main Methods:

  • Utilized an experimental animal model of renal ischemia-reperfusion injury to induce AKI.
  • Assessed cardiac mitochondrial dynamics, focusing on Drp1 expression.
  • Evaluated markers of cellular apoptosis in the heart tissue.

Main Results:

  • Demonstrated dysregulation of mitochondrial dynamics in the heart following AKI.
  • Observed increased Drp1 expression, a key regulator of mitochondrial fission.
  • Confirmed elevated levels of cellular apoptosis in cardiac tissue from the AKI model.

Conclusions:

  • AKI induces significant cardiac mitochondrial injury and apoptosis, contributing to cardiorenal interactions.
  • Mitochondrial dynamics dysregulation is a key mechanism in AKI-induced heart damage.
  • Understanding these mechanisms is crucial for developing novel interventions for CRS and reducing AKI-related mortality.